ClinicalTrials.gg
RecruitingNCT07651852Updated Oct 26, 2026

Globe Registry: Globe® Pulsed Field System Registry Study for Treating Patients With Symptomatic Atrial Fibrillation

An observational study in Atrial Fibrillation, sponsored by Kardium Inc.. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Kardium Inc. · Observational

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 26, 2026Now RecruitingFirst site in United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.

Planned enrollment
97th of 308
500 · median 200
Started
2026
with 47 others
Observational
308 of 993
58 open now
Primary completion
2029-10
later than 196 of 219 live
Registered
983rd of 993
by date

Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 97th largest by planned enrollment of the 308 observational ones that give a count, is one of 48 that started in 2026, is one of 308 observational ones, reaches primary completion later than 196 of the 219 other live ones, and was the 983rd registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 160 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 993 studies in Atrial Fibrillation with a site in United States, or all of them as a file.
02

Study summary

This post-market registry is designed to collect real world data on the use of the Globe PF System for the treatment of atrial fibrillation (AF).

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population consists of AF participants who are scheduled for treatment using the Globe PF System.

Eligibility criteria

Key Inclusion Criteria:

  • Patients with a planned ablation procedure using the commercially available Globe PF System

Key Exclusion Criteria:

  • Patients whose is 1 year or less
  • to left atrial catheter ablation or PF ablation
  • Current enrollment in any study of a medical device, biologic, or drug not pre-approved by Kardium
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Globe Pulsed Field System

    Device: Globe Pulsed Field System

Interventions

  • DeviceGlobe Pulsed Field System

    Ablation and atrial mapping with the Globe Pulsed Field System

06

What researchers measure

Primary outcomes

  1. Effectiveness endpoint

    Rate of 12-month treatment success following ablation using the Globe PF System.

    Time frame: 12 months

  2. Safety endpoint

    Rate of subjects with one or more major adverse events up to 7 days following the index ablation procedure.

    Time frame: 7 days

07

Study locations

2 of 2 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Oct 2029, 36 months after the start.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 36 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Oct 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2026
First posted
Jun 16, 2026
StartActual
Oct 9, 2026was Jul 2026
Primary completionEst.
Oct 2029
CompletionEst.
Oct 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
2 sites added — first site in United States
Show 2 added (2 United States)
  • Arrhythmia Research Group · Jonesboro, United States
  • Overlake Hospital · Bellevue, United States
Oct 26, 2026
Start date
Jul 2026→Oct 9, 2026 (actual)
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in United States
    Show 2 added (2 United States)
    • Arrhythmia Research Group · Jonesboro, United States
    • Overlake Hospital · Bellevue, United States
    Start date Jul 2026→Oct 9, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07651852
Lead sponsor
Kardium Inc.
Responsible party
Sponsor
First posted
Jun 16, 2026
Start date
Oct 9, 2026
Primary completion
Oct 2029 (estimated)
Completion
Oct 2029 (estimated)
Last update
Oct 26, 2026

Study contacts

Clinical Affairs
Contact
Clinical.Affairs@kardium.com
+1 (604) 248 8891

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion